MRTX Company Profile and Key Details
Mirati Therapeutics, Inc.
MRTX Stock Price Chart
Stock Price Today
Mirati Therapeutics, Inc. (MRTX) stock declined over -0.17%, trading at $58.70 on NASDAQ, down from the previous close of $58.80. The stock opened at $58.86, fluctuating between $58.54 and $58.99 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Company Information
| Employees | 587 |
| Beta | 0.77 |
| Sales or Revenue | $12.44M |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Mirati Therapeutics, Inc. (NASDAQ: MRTX) stock price is $58.70 in the last trading session. During the trading session, MRTX stock reached the peak price of $58.99 while $58.54 was the lowest point it dropped to. The percentage change in MRTX stock occurred in the recent session was -0.17% while the dollar amount for the price change in MRTX stock was -$0.10.
The NASDAQ listed MRTX is part of Biotechnology industry that operates in the broader Healthcare sector. Mirati Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Alan Bart Sandler M.D.
Pres & Head of Global Devel. in Oncology
Dr. Kelly Covello Ph.D.
Vice President & Head of Medical Affairs
Dr. Charles M. Baum M.D., Ph.D.
Founder, Interim Chief Executive Officer, Pres, Head of R&D and Director
Mr. Benjamin J. Hickey M.B.A.
Chief Commercial Officer
Ms. Reena R. Desai
Chief Legal Officer & Corporation Sec.
Dr. James G. Christensen Ph.D.
Executive Vice President & Chief Scientific Officer
Ms. Laurie D. Stelzer
Chief Financial Officer
Mr. David D. Meek
Chief Executive Officer & Director
Mr. Ryan Asay
Vice President & Head of Corporation Affairs
Mr. Michael E. Paolucci
Chief People Officer
Mr. John B. Moriarty Jr., J.D.
Corporation Sec.
MRTX's closing price is 115.02% higher than its 52-week low of $27.30 where as its distance from 52-week high of $64.41 is -8.87%.
Number of MRTX employees currently stands at 587.
Official Website of MRTX is: https://www.mirati.com
MRTX could be contacted at phone 858 332 3410 and can also be accessed through its website. MRTX operates from 3545 Cray Court, San Diego, CA 92121, United States.
MRTX stock volume for the day was 20.96M shares. The average number of MRTX shares traded daily for last 3 months was 1.78M.
The market value of MRTX currently stands at $4.12B with its latest stock price at $58.70 and 70.15M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com